BioCryst Pharmaceuticals(NASDAQ) BCRX

BioCryst Pharmaceuticals, Inc. makes pills for rare diseases. These medicines help patients prevent painful swelling attacks. The company also creates treatments for the flu.

What Does BioCryst Make?

• ORLADEYO: Oral pill used to prevent swelling attacks in patients with hereditary angioedema; available in capsules and pellets.
• RAPIVAB: Injected neuraminidase inhibitor used to treat acute uncomplicated influenza in adults and children.
• Navenibart: Investigational monoclonal antibody designed for long-acting prevention of swelling attacks with dosing every 3 or 6 months.
• BCX17725: Selective investigational protein therapy aimed at treating Netherton syndrome, a rare genetic disorder.

Strategic Moves and Expansion

• Completed a merger with Astria Therapeutics in Jan. 2026 to expand the rare disease pipeline.
• Sold the European portion of the ORLADEYO business to Neopharmed Gentili S.p.A. in Oct. 2025.
• Granted exclusive rights to Neopharmed in May 2026 to sell navenibart across Europe.
• Approved a plan in June 2026 to close the Birmingham discovery center to focus on external innovation.
• Began shipping ORLADEYO oral pellets to pediatric patients in the United States in Aug. 2026.

How the Company Stands Out

BioCryst focuses on converting complex biological treatments into oral pills that are easier for patients to use. The company uses specialized commercial infrastructure to support its rare disease products in global markets.

Key Financial Results

• Total revenues were $218.3 million for the three-month period ended June 30, 2026.
• License and other revenues increased by $53.5 million in the second quarter of 2026.
• Net loss reached $643.4 million for the six-month period ended June 30, 2026.
• Cash, cash equivalents, and available investments totaled $352.6 million as of June 30, 2026.
• Revenues from ORLADEYO rose by $14.7 million in the three months ended June 30, 2026.

Bottom Line

BioCryst has transitioned from a research-focused organization into a commercial enterprise specializing in rare disease treatments. The company is now streamlining its internal operations to prioritize its most valuable therapies and strategic partnerships.